{name}
{subtitle}
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
city
~9 mi. (Obninsk, Russia, +383 more cities)
facility
Federal State Institution Medical Radiology Research Center
biomarker
ER Negative, +2 more biomarkers
drug
atezolizumab, +4 more drugs
drug type
chemotherapy, +1 more type
Sasanlimab (PF-06801591) in Combination With BCG or as Single Agent in Participants With High-Risk Non-Muscle Invasive Bladder Cancer
city
~9 mi. (Obninsk, Russia, +153 more cities)
facility
A.Tsyb Medical Research Radiological Center of the Ministry of Health of the Russian Federation
condition
Bladder Urothelial Carcinoma, +2 more conditions
drug
BCG solution, +1 more drug
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
city
~9 mi. (Obninsk, Russia, +93 more cities)
facility
National Medical Research Radiology Centre ( Site 0869)
condition
Bladder Carcinoma, +1 more condition
drug
cisplatin, +4 more drugs
drug type
chemotherapy, +3 more types
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
city
~9 mi. (Obninsk, Russia, +190 more cities)
facility
MRRC n.a. A.F. Tsyb - branch of FSBI "NMRC of Radiology" Minzdrav Russia, +2 more facilities
biomarker
ATM Loss, +27 more biomarkers
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
city
~55 mi. (Podolsk, Russia, +89 more cities)
facility
Podolsk Regional Clinical Hospital ( Site 1907)
biomarker
ER Positive, +2 more biomarkers
drug
capecitabine, +4 more drugs
drug type
chemotherapy, +1 more type
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
city
~64 mi. (Kaluga, Russia, +201 more cities)
facility
Kaluga Regional Clinical Hospital /ID# 221211
drug
azacitidine, +1 more drug
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
city
~70 mi. (Krasnogorsk, Russia, +93 more cities)
facility
MEDSI Clinical Hospital on Pyatnitsky Highway-Departmentof Antitumor Drug therapy ( Site 2618)
drug
belzutifan, +1 more drug
Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)
city
~70 mi. (Krasnogorsk, Russia, +105 more cities)
facility
MEDSI Clinical Hospital on Pyatnitsky Highway-Departmentof Antitumor Drug therapy ( Site 1129)
drug
bevacizumab, +1 more drug
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)
city
~70 mi. (Krasnogorsk, Russia, +13 more cities)
facility
Moscow City Oncology Hospital #62 ( Site 2214)
condition
Fallopian Tube Carcinoma, +2 more conditions
drug
bevacizumab, +3 more drugs
drug type
chemotherapy, +2 more types
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
city
~70 mi. (Krasnogorsk, Russia, +105 more cities)
facility
MEDSI Clinical Hospital on Pyatnitsky Highway-Departmentof Antitumor Drug therapy ( Site 1216)
biomarker
ATM Loss, +62 more biomarkers
condition
Breast Carcinoma, +2 more conditions